Systemic Sclerosis Interstitial Lung Disease: Early Diagnosis and Comprehensive Management
  • CME

Interstitial lung disease (ILD) is a frequent complication of the autoimmune disorder systemic sclerosis (SSc). SSc-ILD remains a challenging condition to identify, treat, and manage. Early identification of ILD in patients with SSc is critical so that treatment can be initiated as soon as possible. However, utilization of optimal screening and diagnosis strategies is low among healthcare providers. Treatment decisions also represent a significant clinical challenge; a lack of guidance and effective treatments results in suboptimal practice and gaps in knowledge among providers. While new agents are on the horizon, dissemination of clinical trial data and uptake of new agents may be delayed. Monitoring of SSc-ILD patients is equally difficult, and research suggests suboptimal practice related to this aspect of care. Finally, poor patient-provider communication amplifies these challenges and contributes to patient anxiety.
Flavia Castelino, MD
Program Director
Jane E. Dematte, MD, MBA
Mary Beth Scholand, MD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Released: September 30, 2019 Expiration: September 30, 2020

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Discuss the epidemiology of ILD in patients with systemic sclerosis.
  • Describe the screening and diagnostic evaluation of patients with SSc for ILD.
  • Examine management options for ILD in patients with SSc.
  • Review how to monitor progression of ILD and treatment response in SSc-ILD.
  • Develop strategies to improve clinician communication with patients with SSc-ILD about their disease.

Information on this Educational Activity

All faculty, staff and reviewers involved in the planning, review or presentation of continuing education activities provided by Purdue University College of Pharmacy are required to disclose to the audience any relevant commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity. All additional planning committee members, staff and reviewers of MCM Education and Purdue University College of Pharmacy have no relationships to disclose.

Program Director

Flavia Castelino, MD

Director, Scleroderma Program
Massachusetts General Hospital
Assistant Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Dr. Castelino discloses the following: Consultant: Boehringer-Ingelheim Grants/Research Support: Scleroderma Research Foundation


Jane E. Dematte, MD, MBA

Professor of Medicine
Northwestern University
Feinberg School of Medicine
Director, Interstitial Lung Disease Program
Division of Pulmonary and Critical Care Medicine
Chicago, Illinois

Dr. Dematte discloses the following: Advisory Board Membership: Boehringer-Ingelheim Honorarium Recipient: Boehringer-Ingelheim
Mary Beth Scholand, MD

Associate Professor and Director of the Interstitial Lung Disease Program
University of Utah
Salt Lake City, Utah

Dr. Scholand discloses the following: Speaker Bureau: Boehringer-Ingelheim, Genentech Advisory Board Membership: Boehringer-Ingelheim, Genentech, Veracyte

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA.

Purdue University requires all faculty to disclose any planned discussion of an investigational and/or off-label use of a pharmaceutical product or device within their presentation. Participants should note that the use of products outside FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for approved indications.

Target Audience

Rheumatologists, pulmonologists, dermatologists, and other healthcare professionals who may encounter and/or treat patients with SSc-ILD.

Physician Continuing Medical Education

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Purdue University College of Pharmacy and MCM Education. Purdue University is accredited by the ACCME to provide continuing medical education for physicians.

Purdue University designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from September 30, 2019, through September 30, 2020:

1. Register online at
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 70% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Pooled data from ACR 2019, reported by CCO, analyzing the safety of filgotinib, an investigational JAK1 inhibitor, through 24 weeks of treatment in patients with RA

Released: November 18, 2019

Audio: New Crohn’s and ulcerative colitis clinical data from ACG and DDW 2018. From Francis A. Farraye, MD, MSc.

Francis Farraye Headshot Francis A. Farraye, MD, MSc Released: November 7, 2018

Full IBD slides: New Crohn’s and ulcerative colitis clinical data from ACG and DDW 2018. From Francis A. Farraye, MD, MSc.

Francis Farraye Headshot Francis A. Farraye, MD, MSc Released: October 25, 2018

Emerging Crohn’s and ulcerative colitis treatments and targets: integrins, JAK inhibitors, IL-12/23 inhibitors, S1P1 modulators, fecal transplant (FMT)

Gary Lichtenstein Headshot Gary R. Lichtenstein, MD Released: October 3, 2018
Provided by
Purdue University Logo

Accreditation: Dawn Sinclair, Purdue University
Certificates/Credits: Heather Holley, Purdue University

This activity is supported by an independent educational grant from
Boehringer Ingelheim Pharmaceuticals, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the,, and Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?